Dublin Protest Calls for HSE Approval of Rare Disease Medication

A public demonstration is taking place in Dublin today as families and advocates push for the Irish Health Service Executive (HSE) to approve the reimbursement of Skyclarys. The medication, which is currently the only treatment developed for the rare neurodegenerative disorder Friedreich’s ataxia, faces a critical hurdle ahead of a final decision by the HSE Senior Leadership Team this Tuesday.

Friedreich’s ataxia is an inherited condition that severely impacts the nervous system, leading to significant challenges with movement and physical coordination. Symptoms often emerge in childhood, and the disease is progressive. The protest comes in response to a recommendation from the HSE Drugs Group, which has advised against funding the drug. Advocates, including Sinéad Maher, whose husband has lived with the condition for over two decades, are seeking a reversal of this position.

During an interview with Newstalk, Maher emphasized that there is historical precedent for the HSE leadership to override negative recommendations from its advisory groups. She highlighted a 2019 instance where management chose to fund a treatment despite initial advice against it. Supporters are hopeful that the leadership will prioritize access to this therapy, viewing the upcoming Tuesday decision as a life-altering turning point for patients currently lacking other pharmaceutical options.